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ORIGINAL ARTICLE
Associations Between Systolic Interarm 
Differences in Blood Pressure and Cardiovascular 
Disease Outcomes and Mortality
Individual Participant Data Meta-Analysis, Development and Validation of a 
Prognostic Algorithm: The INTERPRESS-IPD Collaboration
Christopher E. Clark , Fiona C. Warren, Kate Boddy , Sinead T.J. McDonagh , Sarah F. Moore , John Goddard ,  
Nigel Reed , Malcolm Turner, Maria Teresa Alzamora, Rafel Ramos Blanes , Shao-Yuan Chuang , Michael Criqui,  
Marie Dahl , Gunnar Engström, Raimund Erbel, Mark Espeland, Luigi Ferrucci, Maëlenn Guerchet, Andrew Hattersley,  
Carlos Lahoz, Robyn L. McClelland, Mary M. McDermott , Jackie Price, Henri E. Stoffers, Ji-Guang Wang, Jan Westerink,  
James White, Lyne Cloutier , Rod S. Taylor , Angela C. Shore, Richard J. McManus, Victor Aboyans, John L. Campbell
ABSTRACT: Systolic interarm differences in blood pressure have been associated with all-cause mortality and cardiovascular disease. 
We undertook individual participant data meta-analyses to (1) quantify independent associations of systolic interarm difference with 
mortality and cardiovascular events; (2) develop and validate prognostic models incorporating interarm difference, and (3) determine 
whether interarm difference remains associated with risk after adjustment for common cardiovascular risk scores. We searched for 
studies recording bilateral blood pressure and outcomes, established agreements with collaborating authors, and created a single 
international dataset: the Inter-arm Blood Pressure Difference - Individual Participant Data (INTERPRESS-IPD) Collaboration. Data 
were merged from 24 studies (53 827 participants). Systolic interarm difference was associated with all-cause and cardiovascular 
mortality: continuous hazard ratios 1.05 (95% CI, 1.02–1.08) and 1.06 (95% CI, 1.02–1.11), respectively, per 5 mm Hg systolic 
interarm difference. Hazard ratios for all-cause mortality increased with interarm difference magnitude from a ≥5 mm Hg threshold 
(hazard ratio, 1.07 [95% CI, 1.01–1.14]). Systolic interarm differences per 5 mm Hg were associated with cardiovascular events in 
people without preexisting disease, after adjustment for Atherosclerotic Cardiovascular Disease (hazard ratio, 1.04 [95% CI, 1.00–
1.08]), Framingham (hazard ratio, 1.04 [95% CI, 1.01–1.08]), or QRISK cardiovascular disease risk algorithm version 2 (QRISK2) 
(hazard ratio, 1.12 [95% CI, 1.06–1.18]) cardiovascular risk scores. Our findings confirm that systolic interarm difference is associated 
with increased all-cause mortality, cardiovascular mortality, and cardiovascular events. Blood pressure should be measured in both 
arms during cardiovascular assessment. A systolic interarm difference of 10 mm Hg is proposed as the upper limit of normal.
REGISTRATION: URL: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42015031227 (Hypertension. 
2020;77:00-00. DOI: 10.1161/HYPERTENSIONAHA.120.15997.) • Data Supplement
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Cardiovascular disease is the leading cause of death worldwide, and hypertension is a major risk factor.1 Benefits of hypertension treatment are greatest for individuals with the highest estimated cardiovascu-lar risk,2 but the majority of events occur in individuals with low to medium cardiovascular risk scores, therefore, 
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novel additional risk markers may help to identify individ-
uals most likely to benefit from preventative measures.3 
Cardiovascular risk assessments generally take place in 
primary care settings,4 so ideally risk markers should be 
easily measured, with low acquisition costs for practical 
implementation.5
Measurement of blood pressure (BP) in both arms 
is easily achieved. International hypertension guidelines 
recommend checking BP in both arms and subsequently 
monitoring BP on the higher reading arm.6–9 Guidelines 
also acknowledge the association of systolic interarm BP 
differences (IAD) with cardiovascular risk.6,7 Systolic IADs 
≥10 mm Hg arise in 11% of hypertensive people and in 
4% of the general population.10 Cross-sectional stud-
ies report higher prevalence of systolic IAD in the pres-
ence of diabetes and cardiovascular, cerebrovascular, or 
peripheral arterial diseases.10–12 IAD, after adjustment for 
BP, is associated with increased left ventricular mass,13 
greater arterial stiffness,13–15 diabetic nephropathy,16,17 
and retinopathy.16 Study-level meta-analyses have 
observed associations of IAD with cardiovascular and all-
cause mortality and with increased cardiovascular event 
rates.12,18 Independent risk has also been demonstrated 
for IAD after adjustment for Framingham risk scores.19–21
However, study-level meta-analyses are limited in 
their ability to draw conclusions since they combine stud-
ies with different patient characteristics, methodological 
choices, and analytical approaches. Such limitations can 
be minimized by using individual participant data (IPD).
We established the Inter-arm Blood Pressure Differ-
ence - Individual Participant Data (INTERPRESS-IPD) 
Collaboration to (1) to conduct the first international IPD 
meta-analysis to examine the independent association of 
systolic IAD with risk for cardiovascular events, all-cause 
mortality, and cardiovascular mortality; (2) develop and 
validate new cardiovascular risk prediction models that 
incorporate IAD; and (3) determine whether IAD predicts 
additional risk beyond existing cardiovascular risk scores.
METHODS
Data-sharing agreements were signed with each collaborat-
ing study lead author, and an Independent Monitoring Group 
oversaw conduct. Under terms of the data-sharing agreements 
the INTERPRESS-IPD dataset is not freely available but can 
be discussed with the corresponding author on reasonable 
request. The study protocol is registered with the international 
prospective register of systematic reviews (PROSPERO) and 
has been published.22 This study was conducted in accor-
dance with the PRISMA-IPD (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses of IPD) statement.23
Nonstandard Abbreviation and Acronyms
ASCVD  Atherosclerotic Cardiovascular 
Disease
BP blood pressure
HDL high-density lipoprotein
HR hazard ratio
IAD interarm BP differences
IPD individual participant data
PRISMA-IPD  Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses 
of IPD
QRISK2  QRISK cardiovascular disease risk 
algorithm version 2
SCORE  Systematic Coronary Risk 
Evaluation
Novelty and Significance
What Is New?
• To determine the impact of differences in blood pres-
sure between arms on cardiovascular outcomes (eg, 
heart attack, death), data from over 57 000 individuals 
from 24 studies around the world were collated into 
one large dataset and analyzed.
• Results suggest that interarm differences above 5 mm 
of mercury (mm Hg) predict all-cause mortality, cardio-
vascular mortality and cardiovascular events.
• Results are based on a single pair of measurements 
with blood pressure measured in one arm and then the 
other, and challenge advice that interarm differences in 
blood pressure should be confirmed using a simultane-
ous method (blood pressure measured in both arms at 
the same time).
What Is Relevant?
• Interarm differences in blood pressure identify addi-
tional risk of having a cardiovascular event beyond that 
predicted by existing cardiovascular risk scores alone; 
this could inform clinical decisions regarding primary 
prevention of cardiovascular disease.
Summary
A 10 mm Hg difference in systolic blood pressure 
between arms should now be regarded as an upper 
limit of normal. Checking blood pressure in both arms, 
beyond choosing which arm to measure for the detec-
tion and management of high blood pressure, is a key 
part of cardiovascular risk assessment and should 
become routine clinical practice.
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Literature Search and Study Identification
Medline, Old Medline, Medline in process, Embase, and CINAHL 
were searched (Table S1 in the Data Supplement) for prospective 
studies reporting BP measurement in both arms. Unpublished 
data were sought from collaborators and the OpenGrey data-
base. Searches were undertaken on April 19, 2016 with monthly 
updates until January 2017; dataset submission closed on April 
7, 2017. Citations were screened in Covidence (Veritas Health 
Innovation, Melbourne, Australia) by 2 coauthors (S.F. Moore 
and S.T.J. McDonagh, L. Cloutier, C.E. Clark, J.L. Campbell, R.J. 
McManus, or A.C. Shore) independently; conflicts were resolved 
by discussion, with adjudication by C.E. Clark if unresolved.
Observational longitudinal studies or randomized controlled 
trials without BP lowering interventions, recording recruitment 
BP in both arms, were eligible. Inclusion criteria were partici-
pants aged ≥18 years, recruited from community, primary care, 
or general clinic settings. Primary outcomes were all-cause 
mortality, cardiovascular mortality, or fatal and nonfatal cardio-
vascular events. Selective cohorts such as vascular clinics were 
excluded. Participant and study-level characteristics known 
to relate to cardiovascular risk or BP and IAD measurement 
were sought. These included age, sex, ethnic group, body mass 
index, smoking status, total and HDL (high-density lipoprotein) 
cholesterol, and preexisting diagnoses of hypertension, diabe-
tes, cardiovascular, renal and peripheral arterial diseases, cere-
brovascular disease, and methods of BP measurement.
Data Extraction and Preparation
Eligible study authors were invited to share data; nonresponders 
received 2 reminders. Anonymized data were securely trans-
ferred to the University of Exeter server and cleaned with refer-
ence to published data and author discussion, where necessary. 
Datasets were combined using Stata v14.0 (StataCorp, TX). For 
randomized controlled trials, we excluded interaction effects on 
outcomes between systolic IAD and treatment before including 
both trial arms in the IPD dataset. To overcome varying classifica-
tions of ethnicity, we mapped participants to the most commonly 
observed ethnic groups, seeking author and expert advice where 
required (Table S2). Two authors (S.T.J. McDonagh, L. Cloutier, or 
C.E. Clark) independently assessed study quality using a modi-
fied Quality Improvement in Prognostic Studies tool (Table S3).24
Statistical Analysis
We defined IAD as absolute difference between the first pair 
of systolic arm BP readings. Where baseline BP was also mea-
sured separately to paired measurements during recruitment, we 
used this measurement in adjusted models. If only paired read-
ings existed we adopted the higher reading arm BP.6,7 For the 
inferential analyses and modeling, follow-up analysis times were 
truncated to 10 years. Cardiovascular events were defined as first 
occurrence of myocardial infarction, physician confirmed angina, 
coronary revascularisation, transient ischemic attack, or stroke. 
Preexisting cardiovascular disease was defined as a history of any 
one of these events, or of peripheral arterial disease, at baseline.
Time-to-event outcomes for all-cause mortality, cardiovascu-
lar mortality, and first fatal or nonfatal cardiovascular event were 
investigated using Cox proportional hazards models to derive 
hazard ratios (HR). Initial 2-stage IPD meta-analyses, model-
ing IAD for each study as both a continuous variable and serially 
as dichotomous variables with 1 mm Hg increments up to 20 
mm Hg,25 were used to estimate heterogeneity. This was catego-
rized according to I2 values as low (<25%) moderate (25%–50%) 
or high (>50%).26 All models were adjusted for baseline systolic 
BP, age, and sex.
One-stage random-effects flexible parametric models failed 
to converge (probably due to low between-study heterogeneity). 
Therefore, fixed-effect one-stage Cox proportional hazards mod-
eling, stratified by study, was adopted, as per protocol.22 For prog-
nostic modeling, 4 cohorts (4264 participants) were reserved as 
a validation dataset. Validation cohorts were chosen nonrandomly 
to include participants of both sexes covering the full age range.27 
Two authors (F. Warren and C.E. Clark) independently chose 4 
cohorts then agreed on the final selection by consensus (Figure 
S1).28–31 One-stage Cox proportional hazards models, stratified by 
study, used the remaining cohorts (the derivation dataset) to inves-
tigate effects of participant-level covariates on outcomes with 
inclusion of IAD within the model. Baseline HDL cholesterol was 
missing for 7 studies, so was omitted as a candidate covariate in 
model development. Statistically significant covariates (threshold 
P<0.1) were entered into multivariable models and retained if P 
values were <0.05. Excluded covariates were individually returned 
to check whether inclusion improved model fit, tested with likeli-
hood ratio tests, and the Akaike Information Criterion.32
Final models were validated using calibration slopes and 
internal-external cross-validation analysis, with goodness of fit 
assessed using Harrell C statistic.33 Kaplan-Meier curves for 
derivation and validation cohorts were compared using cutoffs 
approximating to 10-year mortality risks groups of <10%, 10% 
to 20%, and >20%.
For participants without preexisting cardiovascular disease, 
systolic IAD was adjusted using Cox proportional hazards mod-
els stratified by study for 4 guideline-recommended cardio-
vascular risk scores: Atherosclerotic Cardiovascular Disease 
(ASCVD),9,34 Framingham,8,35 QRISK cardiovascular disease risk 
algorithm version 2 (QRISK2),6,36 and the European Systematic 
Coronary Risk Evaluation score (SCORE).7,37 Analyses were 
restricted to validated ethnicities and age ranges for each score 
(ASCVD: 40–79, Framingham: 20–79, QRISK2: 25–84, and 
SCORE: 40–65 years).34–37
Inclusion bias was assessed by comparing outcomes in the 
INTERPRESS-IPD dataset with published cohorts not in the 
Collaboration. Publication bias was assessed visually using a 
funnel plot and quantified with Egger test.38
Following multiple imputation of missing baseline data by 
chained equations, risk modeling was repeated and compared 
with models derived using observed data only; no missing out-
come data were imputed. A total of 32 imputed datasets were 
produced, imputing baseline data across the pooled dataset, 
accounting for study in the imputation algorithm. A 3-person 
Public Advisory Group, facilitated by K. Boddy, was fully integrated 
throughout the study, contributing to bimonthly project meetings 
and facilitating dissemination of findings in accessible ways.
RESULTS
Twenty-four studies contributed data to the Collaboration 
(Figure 1; Table S4); ten others were eligible but unable 
to supply data,21,39–47 and a further 26 were ruled out after 
consultations with authors (Table S5).48–73 Records for 
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53 827 (93.7%) participants contained at least one pair 
of BP readings. Mean age was 60.3 (SD, 12.5; range, 
18–102), 47.8% were female, and baseline BP was 
138.3/80.9 (SD, 21.8/11.8) mm Hg (Table S6). Stud-
ies originated from Western Europe (14), United States 
(7), East Asia (2), and Sub-Saharan Africa (1). Most par-
ticipants were White (76%); other ethnicities were East 
Asian (8.6%), African American (6.0%), Hispanic Ameri-
can (3.8%) Black African (2.0%) with 0.8% unknown 
(coded as other; Table S2) and 2.8% missing. Studies 
recruited subjects from community or primary care regis-
ters (n=20),16,19,28–31,74–87 study recruitment clinics (n=3),88–
90 and a Veterans’ medical service (n=1).20 Participants 
were free of cardiovascular disease in 3 cohorts,11,28,74 had 
diabetes in 2,16,87 hypertension in 119 and were selected 
for intermediate vascular risk (10-year coronary event 
risk between 5 and 15%) in another.86 Remaining cohorts 
were not selected according to cardiovascular risk factors 
(Table S4). Distribution of variables and outcomes by study 
is described in the Tables S7 through S9).
Study quality and assessment of bias
Modified Quality Improvement in Prognostic Studies 
assessments judged 19 datasets to be at low risk of 
bias; 5 were unclear and none high (Table S10); Quality 
Improvement in Prognostic Studies judgments were non-
discriminatory for outcomes. One published IAD study 
Figure 1. PRISMA flow chart for literature search.
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was not included in the INTERPRESS-IPD dataset; het-
erogeneity between HRs for it and included studies was 
low (I2=0%; Figure S1).21 We found no evidence of pub-
lication bias (Egger P=0.657; Figure S2).
Time-to-Event Analyses and Model 
Development
All-Cause Mortality
All-cause mortality was reported in 23 studies with 4939 
(9.2%) deaths (Figure S3). Two-stage random-effects 
modeling in 50 661 cases, adjusted for age, sex, and 
baseline systolic BP, identified that continuous IAD was 
significantly associated with time to all-cause mortality 
(HR, 1.04 [95% CI, 1.01–1.07] per 5 mm Hg of abso-
lute IAD; heterogeneity between studies was moderate 
(I2=35%; Figure S4). Using 35 901 participants from 19 
cohorts with complete data for candidate covariates as the 
derivation dataset systolic, IAD was a significant predic-
tor of mortality (HR, 1.05 [1.02–1.08] per 5 mm Hg) with 
baseline systolic BP, age, sex, ethnicity, current smoking, 
total cholesterol, hypertensive, and diabetic status. Find-
ings using all available data from those cohorts (40 124 
participants) were similar (HR, 1.05 [1.02–1.07] per 5 
mm Hg; Table 1). Harrell C statistic showed overlapping 
values between derivation (0.76 [95% CI, 0.75–0.77]) 
and validation (0.77 [95% CI, 0.75–0.80]) cohorts, with 
an overall pooled calibration slope on internal-external 
cross-validation of 0.97 (95% CI, 0.88–1.06]; Figure S5).
Hazard curves for each risk group showed good over-
lap between derivation and validation cohorts and good 
separation between groups (Figure 2). Using the model 
described above and all available data, dichotomized 
IAD cutoffs at 1 mm Hg increments indicated increas-
ing hazards of all-cause mortality for an IAD rising from 
≥5 mm Hg (HR for IAD ≥5 mm Hg: 1.07 [95% CI, 1.01–
1.14]; I2=0%; 23 studies, 50 661 participants; Figure 3).
After imputation of missing baseline covariates (HDL, 
7 studies; body mass index, 1 study), IAD was no longer 
a significant predictor of all-cause mortality in the fully 
adjusted (IAD plus all covariates found to be statistically 
significant) model (Table S11).
Cardiovascular Mortality
Cardiovascular deaths were reported for 1435 (3.0%) of 
48 261 participants from 21 studies (Figure S3). Con-
tinuous systolic IAD, adjusted for age, sex, and baseline 
systolic BP was significantly associated with cardiovas-
cular mortality (HR, 1.07 [95% CI, 1.03–1.12]; I2=11%) 
per 5 mm Hg of IAD (Figure S6). The derivation dataset 
for cardiovascular risk modeling consisted of 18 studies 
(33 650 participants with complete case data). The final 
model included systolic IAD (HR, 1.06 [95% CI, 1.02–
1.11] per 5 mm Hg) and, apart from total cholesterol, 
the same coefficients as the all-cause mortality model 
(Table 2). Harrell C statistics were good and overlapped 
for the derivation (0.80 [95% CI, 0.79–0.82]) and valida-
tion (0.83 [95% CI, 0.79–0.87]) cohorts. Internal-external 
cross-validation gave a pooled calibration slope of 0.97 
(95% CI, 0.83–1.10; Figure S7). Continuous systolic IAD 
remained a significant predictor of cardiovascular mor-
tality after imputation of missing covariates (Table S12).
Fatal and Nonfatal Cardiovascular Events
Of 51 405 participants in 23 studies, 5800 (11.3%) had 
an event within 10 years. In the 2-stage random-effects 
model, continuous systolic IAD was associated with greater 
risk for any cardiovascular event after adjustment for age, 
sex, and baseline systolic BP (HR, 1.03 per 5 mm Hg 
increment [95% CI, 1.00–1.06]; I2=25%; Figure S8). In the 
1-stage fixed-effect model, continuous systolic IAD was 
not associated with risk of events (HR, 1.01 per 5 mm Hg 
increment [95% CI, 0.99–1.03], P=0.174); therefore, mul-
tivariable modeling was not pursued as per protocol. After 
Table 1. Results of One-Stage Meta-Analysis to Develop Overall Final Model for All-Cause Mortality
Covariate
Development dataset, complete case data; 16 stud-
ies, 35 901 participants
Development dataset, all available case data; 19 
studies, 40 124 participants
HR (95% CI) P value HR (95% CI) P value
Systolic IAD per 5 mm Hg 1.05 (1.02–1.08) <0.001 1.05 (1.02–1.07) <0.001
Baseline SBP per 10 mm Hg 1.03 (1.01–1.05) 0.002 1.03 (1.01–1.04) 0.003
Age 1.11 (1.10–1.11) <0.001 1.11 (1.10–1.11) <0.001
Sex (reference: female) 1.63 (1.51–1.77) <0.001 1.62 (1.51–1.74) <0.001
Smoking status 1.89 (1.74–2.06) <0.001 1.91 (1.77–2.06) <0.001
Ethnic group* (reference: 
white)
African American: 1.27 (1.10–1.46) Global: 0.038 African American: 1.27 (1.10–1.46) Global: 0.042
Hispanic-American: 0.94 (0.78–1.13)  Hispanic-American: 0.96 (0.80–1.15)
Other: 0.76 (0.62–0.94) Other: 0.76 (0.62–0.94)
Total cholesterol 0.94 (0.91–0.98) <0.001 0.94 (0.91–0.97) <0.001
Hypertension diagnosis 1.13 (1.03–1.23) 0.007 1.12 (1.03–1.22) 0.006
Diabetes diagnosis 1.49 (1.36–1.63) <0.001 1.52 (1.39–1.66) <0.001
HR indicates hazard ratios; and IAD, interarm blood pressure differences.
*Black African and East Asian categories omitted from model.
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imputation of missing data, however, systolic IAD became a 
significant predictor of outcome (Table S13).
Interarm Difference and Existing Cardiovascular 
Risk Models
Systolic IADs remained significantly associated with fatal 
or nonfatal cardiovascular events over 10 years after 
adjustment for the ASCVD, Framingham, or QRISK2 
risk scores: residual HRs for an IAD ≥10 mm Hg ranged 
from 1.2 to 1.4 (Table 3). As continuous variables, HRs 
per 5 mm Hg increment of systolic IAD was 1.04 (95% 
CI, 1.01–1.08) when adjusted for the Framingham score, 
1.04 (95% CI, 1.00–1.08) for ASCVD and 1.12 (95% 
CI, 1.06–1.18) for QRISK2, representing 4% to 12% 
increases in 10-year cardiovascular risk scores (Figure 
S9). After restricting analyses to a cohort eligible by age for 
Figure 2. Kaplan-Meier plots 
comparing all-cause mortality for the 
derivation and validation cohorts for 
3 risk groups corresponding to 10% 
and 20% 10-year risk thresholds.
Figure 3. All-cause mortality hazard ratios for systolic interarm difference in fully adjusted model.
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all 3 risk scores (40–79 years), variation in HRs between 
scores was minimized (Table 3). The HR of IAD for cardio-
vascular mortality, after adjustment for SCORE in 18 239 
participants was not statistically significant (HR, 1.07 per 
5 mm Hg increment [95% CI, 0.97–1.18]; P=0.178).
DISCUSSION
This is the first international IPD meta-analysis to report 
and model the risks of all-cause mortality, cardiovascu-
lar mortality, and fatal or nonfatal cardiovascular events 
associated with a systolic IAD. We have developed and 
validated multivariable risk models incorporating IAD 
to predict all-cause and cardiovascular mortality and 
demonstrated that IAD remains associated with addi-
tional risk of cardiovascular events after adjustment for 3 
currently used cardiovascular event risk prediction scores.
People with an IAD ≥5 mm Hg had higher mortality 
rates than those with an IAD <5 mm Hg. Each 1 mm Hg 
increment in IAD was associated with approximately a 
1% inflation of a given 10-year risk for all-cause mor-
tality and a 1% to 2% inflation of 10-year risk of car-
diovascular death. These prospective findings are based 
on a single pair of BP measurements, the most readily 
available means of measuring IAD, and so are of direct 
relevance to current clinical practice.
Previous studies have generally failed to observe a 
dose-response association of rising HRs for mortality with 
Table 2. Results of One-Stage Meta-Analysis to Develop Overall Final Model for Cardiovascular 
Mortality
 
Covariate
Development dataset, complete case data; 
15 studies, 33 650 participants
Development dataset, all available case 
data; 18 studies, 38 908 participants
HR (95% CI) P value HR (95% CI) P value
Systolic IAD 
per 5 mm Hg
1.06 (1.02–1.11) 0.007 1.06 (1.02–1.10) 0.007
Baseline SBP 
per 10 mm Hg
1.04 (1.01–1.08) 0.014 1.05 (1.02–1.08) 0.009
Age 1.13 (1.12–1.14) <0.001 1.13 (1.12–1.13) <0.001
Sex (reference: female) 1.65 (1.43–1.90) <0.001 1.73 (1.53–1.97) <0.001
Smoking status 1.66 (1.42–1.94) <0.001 1.69 (1.47–1.95) <0.001
Ethnic group* (reference: 
white)
African American: 1.45 
(1.05–2.00)
0.257 African American: 1.48 
(1.07–2.03)
0.452
Hispanic American: 1.07 
(0.7–1.61)
 Hispanic American: 1.10 
(0.73–1.64)
Other: 0.70 (0.44–1.11) Other: 0.79 (0.52–1.22)
Hypertension diagnosis 1.51 (1.26–1.80) <0.001 1.45 (1.24–1.70) <0.001
Diabetes diagnosis 1.87 (1.61–2.18) <0.001 1.93 (1.67–2.23) <0.001
HR indicates hazard ratios; IAD, interarm blood pressure differences; and SBP, systolic blood pressure.
*Black African and East Asian categories omitted from model.
Table 3. Hazard Ratios for First Cardiovascular Fatal and Nonfatal Events for Interarm Differences Adjusted 
for 10-Year Cardiovascular Risk Scores
Risk score
Number 
(studies)
Mean 10-year 
risk score (SD)* sIAD ≥10 mm Hg Continuous sIAD per 5 mm Hg
  Hazard ratio (95%CI) P value Hazard ratio (95%CI) P value
All complete case data within eligible age range for risk score analyzed
 QRISK2† 9641 (5) 17.2 (12.5) 1.37 (1.18–1.59) <0.001 1.12 (1.06–1.18) <0.001
 ASCVD 19 081 (15) 13.1 (12.7) 1.15 (1.03–1.28) 0.016 1.04 (1.00–1.08) 0.030
 Framingham 23 802 (15) 20.3 (15.8) 1.15 (1.03–1.28) 0.010 1.04 (1.01–1.08) 0.013
Sensitivity analysis—complete cases aged 40 to 79 only, eligible for all 3 risk score calculations
 QRISK2 7140 (5) 17.0 (11.6) 1.32 (1.12–1.58) 0.001 1.09 (1.03–1.16) 0.004
 ASCVD 7140 (15) 16.1 (12.1) 1.31 (1.10–1.56) 0.002 1.09 (1.03–1.16) 0.004
 Framingham 7140 (15) 22.0 (16.0) 1.32 (1.11–1.57) 0.002 1.10 (1.03–1.16) 0.003
ASCVD: risk algorithm (pooled cohort equation). ASCVD indicates Atherosclerotic Cardiovascular Disease; and sIAD, systolic interarm blood 
pressure difference.
*10-year risk of fatal and nonfatal cardiovascular events.
†QRISK2 requires additional variables (atrial fibrillation, chronic kidney disease, and body mass index), hence lower numbers of complete cases 
and eligible cohorts.
D
ow
nloaded from
 http://ahajournals.org by on January 5, 2021
OR
IG
IN
AL
 A
RT
IC
LE
Clark et al Interarm Blood Pressure Differences and Mortality
8  February 2021 Hypertension. 2021;77:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.15997
increasing IADs, as now demonstrated after adjustment 
in this IPD analysis.12,18,74 This supports the case for IAD 
as a marker of cardiovascular risk.91 Our findings confirm 
the risk associated with IAD after adjusting for Framing-
ham risk scores and, for the first time, also show this addi-
tional cardiovascular risk after adjustment for ASCVD or 
QRISK2 scores in patients without cardiovascular disease 
at baseline.19–21 This suggests that the additional impact of 
IAD on risk should be considered when assessing cardio-
vascular risk using existing risk equations. This approach 
is consistent with guidelines to recognize additional indi-
vidual cardiovascular risk factors that are not incorpo-
rated in risk scores.7 IAD was not a significant predictor 
of cardiovascular mortality after adjustment for SCORE. 
Gradual improvements in secondary prevention mean 
fewer cardiovascular deaths now occur as a proportion of 
total events, rendering prediction of fatal events alone less 
clinically relevant. The cardiovascular death rate over 10 
years in SCORE eligible participants in this study was only 
192 out of 20 785 (0.9%) in comparison to 7934 out of 
205 178 (3.9%) in the original SCORE derivation study.92
Current European and National Institute for Health 
and Care Excellence guidance note that a systolic IAD 
>15 mm Hg is associated with additional cardiovascu-
lar risk.6,7 Our findings confirm previous individual cohort 
study findings of risk arising for IADs from the lower 
threshold of ≥ 5 mm Hg.20,74,89 Sequential measurement 
of arms can overestimate magnitude of IADs compared 
with simultaneous measurement but also has a high neg-
ative predictive value in ruling out a simultaneous IAD.16,93 
Taking a conservative view of our findings, we think that 
a 10 mm Hg difference can now be reasonably regarded 
as an upper limit of normal for systolic IAD measured 
sequentially during routine assessment. This information 
should be incorporated into future guidelines and clinical 
practice in assessing cardiovascular risk.
Guidelines advise checking BP in both arms when 
assessing people for hypertension but are widely 
ignored.6,7,94 Failure to check both arms risks errors in 
BP interpretation and management and suboptimal BP 
control.95,96 Uptake of bilateral arm BP measurement is 
increasing but has not yet become standard care.97 Our 
findings show how IAD identifies additional cardiovascu-
lar risk beyond ASCVD, Framingham, or QRISK2 scores 
alone. This could inform decision-making with individuals 
about primary prevention of cardiovascular disease. These 
results are based on IAD derived from a single sequen-
tial pair of BP measurements, easily obtained in practice, 
and challenge advice that IAD should be confirmed using 
simultaneous measurement during clinical assessment.7
Study Limitations
Comprehensive searches were undertaken for cohorts that 
reported either IAD or ankle-brachial index. Additional data 
were identified through author contacts.77,81,82,88,89 In total, 
we combined data from 24 of 34 confirmed eligible studies, 
representing two-thirds of potentially eligible participants, 
and comparison with the one published eligible IAD study 
that we did not obtain showed no evidence of inclusion bias. 
These IPD meta-analyses have required considerable data 
cleaning and preparation; closure of data inclusion in 2017 
means that we could have excluded relevant recent publi-
cations, however, continued search updates to April 2020 
have only identified one new potentially eligible study.98 Our 
search strategy could have missed cohorts or registries 
holding bilateral BP data if no linked IAD or ankle-brachial 
index publications exist. We did not search specifically for 
pulse-wave velocity studies but are aware that recent tech-
nology for measuring this can generate bilateral BP data.99
We derived and validated risk models for all-cause and 
cardiovascular mortality, which, in addition to IAD, included 
risk markers congruent with previously published risk mod-
els.100 Participants were largely based not only in North 
America and low risk (according to SCORE definition) 
European countries37 but also included Asia and sub-Saha-
ran Africa, thus offering relevance to a range of populations. 
Since residual confounding with existing risk scores may 
make it easier to show that a new marker improves predic-
tion, we regard our de novo derived risk models as key dem-
onstrations of the contribution of IAD to risk prediction.101 
The amount of missing data varied widely across studies 
and across variables. Sensitivity analyses incorporating 
multiple imputation of missing data were carried out on the 
assumption that missing data are missing at random. Some 
discrepancies between results of models using observed 
data alone and models using observed and imputed data 
were noted, suggesting that the missing at random assump-
tion may not be valid; however, we emphasize that the mod-
els using observed data only were our primary outcomes.
No intervention studies based on detection of an IAD 
exist, and it is vital that novel risk markers are fully evalu-
ated.102 In general, there is a paucity of evidence that inter-
ventions based on cardiovascular risk result in reductions in 
mortality.103 This study has incorporated IAD into multivari-
able risk models but these will need prospective evaluation.
Conclusions
This study demonstrates and quantifies the independent 
association of IAD with cardiovascular events and mor-
tality. Findings based on a single pair of sequential BP 
readings suggest a reduction of the currently accepted 
normal systolic IAD to a limit of 10 mm Hg can be justified. 
These findings are relevant to primary care practice and 
to low resource settings. BP should be measured in both 
arms when undertaking cardiovascular assessments.
Perspectives
Associations of sequentially measured systolic interarm 
differences in BP with all-cause mortality, cardiovascular 
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mortality, and events were investigated in a multina-
tional individual participant data meta-analyses including 
53 827 participants. Adjusted associations of IAD with 
all-cause mortality and cardiovascular mortality were con-
firmed, and models incorporating IAD were developed and 
validated. Interarm differences were also associated with 
higher risks of cardiovascular events after adjustment for 
commonly used cardiovascular risk scores. BP should 
be measured in both arms during cardiovascular assess-
ment. Further research is needed to determine whether 
selection of intensive cardiovascular risk reduction strate-
gies, on the basis of a detected interarm difference, can 
modify outcomes for people with an interarm difference.
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